CEO Today Magazine Features Exclusive Interview with Co-Diagnostics Inc CEO Dwight Egan
May 13 2019 - 7:00AM
CEO Today Magazine Features Exclusive Interview with
Co-Diagnostics Inc CEO Dwight Egan
New York City, New York – The
May 2019 issue of the prestigious CEO Today Magazine will include
an interview with the CEO of Co-Diagnostics, Inc. (Nasdaq:
CODX), a molecular diagnostics company with a unique,
patented platform for the development of molecular diagnostic
tests, and client of BDA International. The interview provides
details on a variety of subjects, including a layman’s explanation
of how polymerase chain reaction (PCR) works, the PCR technologies
used by the Company, and their applications (liquid biopsy/early
cancer detection, AgBio production, and next generation DNA
sequencing, in addition to infectious disease diagnostics).
Mr. Egan also describes how their proprietary platform lowers
overheads and creates cost savings passed on to the end users.
CEO Today is a go-to source for CEOs and C-level
executives around the world, filled with the latest corporate
developments, business news, and technological innovations.
Interview snapchat: On discussing the size
of the market and potential reach of their products, Mr. Egan
remarks:
The molecular diagnostics market as a whole has
seen incredible growth over the last several years, and has been
projected to exceed $12.5 billion over the next 5 years. With that
growth has come interest from enterprise and non-profit
participants alike, which interest has in turn spurred developments
in many different applications of PCR testing technology. This
market includes infectious disease detection, cancer detection,
genetic sequencing and others—all areas where we believe our
technology brings further value and innovation.
Release of the interview follows recent news by Co-Diagnostics
that a provisional patent has been filed related to its single-step
next generation sequencing (NGS) library preparation methods and
composition.
The interview in full can be found here:
https://bit.ly/2LDxpBU
About BDA International,
Inc.:
BDA International is an independent global
Investor Relations firm offering a wide range of IR-related
analysis, research and advisory services. In particular, we provide
and are compensated for service packages that include strategic
action plans and investor/market perception studies to help
entities improve communication with customers and investors, and to
increase their visibility. BDA International has received no direct
compensation related to this release but its principles may also in
some circumstances hold some of shares of client companies in our
personal portfolios, including CODX. BDA International accepts sole
responsibility for the content and distribution of the foregoing
release, which does not contain any previously unpublished or
non-public information. Parties interested in learning more about
the relationship between BDA and CODX may do so via the contact
information at the bottom of this release.
Disclaimer
Co-Diagnostics is a client of BDA
International. The information, opinions and analysis contained
herein are based on sources believed to be reliable, but no
representation, expressed or implied, is made as to its accuracy,
completeness or correctness. The opinions contained in this
analysis reflect our current judgment and are subject to change
without notice. We do not accept any responsibility or liability
for any losses, damages or costs arising from an investor’s or
other person’s reliance on or use of this analysis. This analysis
is for information purposes only, and is neither a solicitation to
buy nor an offer to sell securities, nor a recommendation of any
security, although members of the BDA may at times hold a position
in the company covered within the article. Past gains are not a
representative of future gains. The opinions herein contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements concerning manufacturing, marketing, growth,
and expansion. When used herein, the words “anticipate,” “intend,”
“estimate,” “believe,” “expect,” “plans,” “should,” “potential,”
“forecast,” and variations of such words and similar expressions
are intended to identify forward-looking statements. Such
forward-looking information involves important risks and
uncertainties that could affect actual results and cause them to
differ materially from expectations expressed herein. A company’s
actual results could differ materially from those described in any
forward-looking statements contained herein. BDA is not a licensed
broker, broker dealer, market maker, investment advisor, analyst or
underwriter. We recommend that you use the information found herein
as an initial starting point for conducting your own research in
order to determine your own personal opinion of the companies
discussed herein before deciding whether or not to invest. You
should seek such investment, tax, financial, accounting or legal
advice appropriate for your particular circumstances. Information
about many publicly traded companies and other investor resources
can be found at www.sec.gov. Investing in securities is speculative
and carries risk.
Investor Relations
Contact:
BDA International www.bda-ir.com
dost@bda-ir.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024